Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31029376 | 0.90 | LTA4H (0.32) | — | |
| SCHEMBL30787611 | 0.90 | LTA4H (0.32) | — | |
| SCHEMBL19720763 | 0.81 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL30787619 | 0.81 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL13895149 | 0.81 | KCNQ3 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL21625324 | 0.76 | KMT2A (0.34) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL27144799 | 0.76 | HRH1 (0.36) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL30022400 | 0.75 | HRH1 (0.35) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL27189838 | 0.75 | HRH1 (0.35) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL20711677 | 0.73 | KCNQ3 (0.34) | KMT2AMEN1KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044570-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |